莫诺帕制药

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $105
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $125 to $133
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Cantor Fitzgerald Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $109
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)
  TipRanks · 2026/4/21
• 评级变动
  Lake Street Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $103
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $123
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27
  \u5e02\u573a\u8d44\u8baf · 2026/5/18
• 评级变动
  A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $130
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
  TipRanks · 2026/9/22
• 评级变动
  BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117
  \u5e02\u573a\u8d44\u8baf · 2026/6/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。